Similarly, SNX631-6 [an equipotent analog of SNX631 (11)] potentiated the tumor-suppressive effect of the AKT inhibitor capivasertib in MDA-MB-468 xenografts, but since capivasertib did not fully suppress tumor growth, it was not possible to conclude whether the effect of SNX631-6 was due to the prevention of tumor adaptation to capivasertib (Fig. 3D). This evidence concerns the gene AKT1 and neoplasm.